Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction

2021 ◽  
Vol 78 (11) ◽  
pp. 1166-1187
Author(s):  
Ambarish Pandey ◽  
Sanjiv J. Shah ◽  
Javed Butler ◽  
Dean L. Kellogg ◽  
Gregory D. Lewis ◽  
...  
Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Rohan Shah ◽  
Paul Coen ◽  
Mark T Gladwin ◽  
Daniel E Forman

Introduction: Prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, especially among older adults. HFpEF is commonly associated with exercise intolerance and skeletal muscle weakening which likely contribute to functional decline. We studied the utility of nitrite (NO 2 ) supplementation with the aim to augment skeletal muscle mitochondrial respiration. Hypothesis: NO 2 administered via oral supplements would be associated with improved mitochondrial respiration. Whereas prior studies with other oral and inhaled nitrate and NO 2 therapy in HFpEF patients have been inconsistent, we used novel NO 2 capsules that we hypothesized would achieve higher serum levels of nitrite and nitrate, and greater cellular and clinical benefits. Methods: A randomized, placebo-controlled pilot trial to study the utility of oral sodium (Na) NO 2 over 4 weeks in an older population (≥70 years) was done. Participants received 20 or 40 mg Na-NO 2 supplements 3 times daily based on their hemodynamic responses. Pre- and post-NO 2 intervention participants underwent biopsies of the vastus lateralis muscle with associated assessments of mitochondrial respiration in permeabilized fibers and also completed cardiopulmonary exercise test. Results: 15 participants were randomized and 13 completed the interventions (n=6 on NO 2 , n=7 on placebo, 69% men, mean age 75.7 years, range 70-91). Post-intervention serum NO 2 level increased (+0.61±0.67 μmol on NO 2, +0.25±0.15 on placebo). Ex-vivo analysis of mitochondrial respiration showed increased O 2 consumption in muscle (+27.1±27.4 pmol/(s*mg) on NO 2 , -11.7±11.3 on placebo). Rated perceived exertion during steady-state walking decreased (-1.2±2.0 on NO 2, +0.2±1.6 on placebo). Peak oxygen uptake (VO 2 ) increased (+1.4±5.2 ml/kg/min on NO2, -3.4±5.2 on placebo). Conclusion: Our study demonstrated efficacy and potential clinical utility of oral NO 2 supplementation in older HFpEF patients with an internally consistent physiologic composite of improved skeletal muscle mitochondrial respiration in association with improved cardiorespiratory fitness and diminished perceived exertion during steady-state walking. Clinical implications are auspicious and further research is indicated.


2021 ◽  
Vol 17 (3) ◽  
pp. 397-413
Author(s):  
Andrea Salzano ◽  
Mariarosaria De Luca ◽  
Muhammad Zubair Israr ◽  
Giulia Crisci ◽  
Mohamed Eltayeb ◽  
...  

2019 ◽  
Vol 68 (3) ◽  
pp. 665-666
Author(s):  
Kenichi Matsushita ◽  
Kazumasa Harada ◽  
Tetsuro Miyazaki ◽  
Takamichi Miyamoto ◽  
Shun Kohsaka ◽  
...  

2015 ◽  
Vol 8 (2) ◽  
pp. 286-294 ◽  
Author(s):  
Bishnu P. Dhakal ◽  
Rajeev Malhotra ◽  
Ryan M. Murphy ◽  
Paul P. Pappagianopoulos ◽  
Aaron L. Baggish ◽  
...  

2020 ◽  
Vol 75 (11) ◽  
pp. 679
Author(s):  
Emily Lau ◽  
Shahrooz Zarbafian ◽  
Ruslan Ilyasovich ◽  
John Sbarbaro ◽  
Robyn Farrell ◽  
...  

2015 ◽  
Vol 9 ◽  
pp. CMC.S21372 ◽  
Author(s):  
Muhammad Asrar Ul Haq ◽  
Cheng Yee Goh ◽  
Itamar Levinger ◽  
Chiew Wong ◽  
David L. Hare

Reduced exercise tolerance is an independent predictor of hospital readmission and mortality in patients with heart failure (HF). Exercise training for HF patients is well established as an adjunct therapy, and there is sufficient evidence to support the favorable role of exercise training programs for HF patients over and above the optimal medical therapy. Some of the documented benefits include improved functional capacity, quality of life (QoL), fatigue, and dyspnea. Major trials to assess exercise training in HF have, however, focused on heart failure with reduced ejection fraction (HFREF). At least half of the patients presenting with HF have heart failure with preserved ejection fraction (HFPEF) and experience similar symptoms of exercise intolerance, dyspnea, and early fatigue, and similar mortality risk and rehospitalization rates. The role of exercise training in the management of HFPEF remains less clear. This article provides a brief overview of pathophysiology of reduced exercise tolerance in HFREF and heart failure with preserved ejection fraction (HFPEF), and summarizes the evidence and mechanisms by which exercise training can improve symptoms and HF. Clinical and practical aspects of exercise training prescription are also discussed.


Sign in / Sign up

Export Citation Format

Share Document